- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07567560
The Short Sleep Study
2026년 8월 6일 업데이트: Danisco
The Short Sleep Study: A Non-interventional Study of Fecal Microbiota in Natural Short Sleepers
Natural Short Sleepers are defined as individuals who sleep fewer than 6 hours per night without any impact on health or daytime mental fatigue levels.
Emerging evidence suggests that, in the general population, the gut microbiota would be negatively influenced by this sleep duration.
It is possible that Natural Short Sleepers have a distinct gut microbiome.
Identifying differences in microbiota composition may lead to an opportunity to improve health outcomes in those with inadequate or poor sleep.
연구 개요
상태
모병
연구 유형
관찰
등록 (추정된)
34
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Florida
-
Miami, Florida, 미국, 33155
- 모병
- Global Life Research Network
-
연락하다:
- Emily Lozano
- 전화번호: (786) 558-8892
- 이메일: emily@globalliferesearch.com
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02111
- 모병
- Lindus Health
-
연락하다:
- Patient Recruitment Coordinator
- 전화번호: 833-711-1429
- 이메일: shortsleep@lindushealth.com
-
-
New York
-
Garden City, New York, 미국, 11530
- 모병
- AccuMed
-
연락하다:
- Leanne Cossu
- 전화번호: 516-746-2190
- 이메일: accumed@aol.com
-
-
Texas
-
Houston, Texas, 미국, 77082
- 모병
- New Dawn Wellness and Medical Research Center
-
연락하다:
- Moses Ukazu
- 전화번호: 281-809-5467
- 이메일: mukazu@ndwmc.com
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
아니
샘플링 방법
비확률 샘플
연구 인구
Natural Short Sleepers are defined as individuals who sleep between 4 and 5.5 hours per night without any impact on health or daytime mental fatigue levels.
설명
Inclusion:
- Men between 20 - 50 years of age and pre-menopausal women between 20 - 45 years of age (inclusive).
- Consistent schedule during daytime hours.
- Body Mass Index (BMI) 18.5 - 35 kg/m2 (inclusive).
- Good physical and mental health as established by self-reported medical history and evaluated by a study investigator.
- Willingness to maintain and record their general habits, eating, and daily activity/exercise pattern for the study period.
- Willingness to maintain typical sleep hygiene patterns (e.g. sleep location, temperature, environment).
- Willingness to maintain their current pattern of alcohol consumption for the duration of the study.
- Willing and able to participate fully in all aspects of the study and complete all study procedures, including providing signed informed consent.
- Willing and able to attend two in-person visits at a trial site
- Completes all required procedures (screening questionnaire and ePROs) during the 14-day screening period 10a. Two instances of the sleep diary and Karolinska Sleepiness Scale may be missed by the participant without impacting eligibility
- Has regular bowel habits, on at least 5 days a week.
- Pittsburgh Sleep Quality Index (PSQI) global score of ≤7 and a sleep efficiency score of ≥80%, self-reported during the screening period. Additionally, no more than one score of 3 is permitted across Question 5 sub-items, and no score of 3 is permitted in Question 10 sub-items, if a bed partner is present
- Sleep, on average, 4-5.5 hours per night, verified via participant self-report during the screening period. If the participant's average is within the 4-5.5 hour range but slept more than 5.5 hours on any of the nights their eligibility will be assessed per PI/Sponsor discretion. Note: Oura ring data from the run-in period will be reviewed to confirm eligibility based on PI/Sponsor discretion.
- Report feeling refreshed with no desire to nap during the daytime, with a score of ≤4 on the Epworth Sleepiness Scale (ESS) evaluated during the screening period.
- Average KSS Score of 1-3 during the screening period.
Exclusion:
- Ever diagnosed with or self-reports a sleep disorder, including sleep apnea, habitual snoring (defined as loud, persistent snoring 3 or more nights per week), insomnia, narcolepsy, or parasomnias.
- Extreme chronotypes, those who regularly go to sleep prior to 8:00pm.
- Any current diagnosed or self-reported gastrointestinal disorder, including Crohn's disease, ulcerative colitis, celiac disease, IBS, or functional bowel disorder or chronic heartburn.
- Regularly wakes up during the night 5 or more times per night for a cumulative amount of 30 minutes as observed via self-report during the screening period, per PI discretion.
- Currently taking medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
- Have taken in the last 3 months medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
- Neurodegenerative diseases (including multiple sclerosis, Parkinson's disease, Alzheimer's disease, dementia).
- Recent history (past year) of alcohol abuse or dependence. Defined as regularly drinking more than 12 drinks for females and more than 20 drinks for males per week and based on PI discretion.
- Drug abuse or dependence, including consistent recreational substance use such as marijuana.
- Binge drinking behavior, defined as 4 or more alcoholic drinks for women or 5 or more alcoholic drinks for men in one sitting on 2 or more occasions, within the past 1 month with final decision per PI discretion.
- Recent history (current use or within the past 1 month) of smoking, vaping or other use of nicotine-containing products.
- Diagnosed neuropsychiatric disorders or symptoms possibly affecting sleep e.g. (generalized anxiety disorder (GAD), major depressive disorder (MDD), bipolar disorder, schizophrenia)
- Any use of systemic antibiotics in the past 3 months. This does not include topical or targeted antibiotic use (ointment, spray, eye drop, ear drop).
- Any use of probiotic supplements in the past 2 weeks.
- Any use of proton pump inhibitors (PPIs) in the past 2 weeks.
- Any use of laxatives or antidiarrheals in the past 4 weeks.
- Any use of non-steroidal anti-inflammatory drugs (NSAIDs) for 5 or more consecutive days in the past 4 weeks.
- Pregnant or breastfeeding or planning to become pregnant.
- Personal circumstances affecting stress or sleep (e.g. serving as a caretaker/required to wake up during sleep/major change in personal life). Note: Life situations causing stress or challenges in sleep that are considered shortterm, per PI discretion, may be considered for re-screening 4 weeks after the life situation has resolved, meaning it is no longer causing stress or challenges in sleep.
- Planned overnight travel during the study.
- Females experiencing perimenopausal or menopausal symptoms, or those who have been diagnosed as perimenopausal or menopausal by a physician.
- Any diagnosed condition or undiagnosed symptom which disrupts sleep, including, but not limited to, hyperthyroidism, night sweats, restless legs, or poorly controlled allergic rhinitis.
- Varying work schedule and/or shift workers who work overnight shifts (e.g. 3rd shift, working late night to early morning hours).
- Any other personal or medical condition that the investigator believes may bias or confound the results.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Natural Short Sleepers
Natural short sleepers (NSS) sleep on average <6 hours per night, but feel no need to sleep longer, and do not show signs of daytime sleepiness or fall asleep in low stimulus environments.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Microbiome characterization of the short sleeper population
기간: baseline through day 10 of the study period.
|
Identify a specific fecal microbiota composition related to short sleep
|
baseline through day 10 of the study period.
|
|
Comparison of natural short sleeper microbiomes to participants from the night owl study.
기간: From baseline through day 10 of the study period.
|
Compare microbiome (composition and function) of natural short sleeprs to those individuals enrolled into the night owl study.
|
From baseline through day 10 of the study period.
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2025년 10월 23일
기본 완료 (추정된)
2026년 12월 1일
연구 완료 (추정된)
2027년 4월 1일
연구 등록 날짜
최초 제출
2025년 11월 10일
QC 기준을 충족하는 최초 제출
2026년 4월 30일
처음 게시됨 (실제)
2026년 5월 5일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 8월 7일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 6일
마지막으로 확인됨
2025년 11월 1일
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- IFF-NO-002
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .